Patients with standard-risk multiple myeloma who stopped lenalidomide maintenance after two years survived just as long as those who stayed on the drug indefinitely, according to results from a large phase 3 trial published in the New England Journal of Medicine. The ENDURANCE trial, sponsored by the ECOG-ACRIN Cancer Research Group, randomized patients after proteasome inhibitor–lenalidomide induction and found no overall survival penalty for the fixed-duration arm. The finding directly challenges years of clinical practice built around continuous maintenance and raises a pointed question: if survival is the same, what are patients gaining by taking a drug with known side effects for years longer than necessary?
Why stopping lenalidomide at two years changes the calculus for patients
Lenalidomide maintenance after initial treatment has been standard care for newly diagnosed myeloma for roughly a decade. Trials that evaluated lenalidomide maintenance until progression helped cement the idea that longer treatment meant better disease control. That approach carried real costs for patients: ongoing fatigue, neuropathy, infection risk, and the cumulative burden of daily medication. The open question was whether those trade-offs actually bought more time alive.
The ENDURANCE trial was designed to answer that question in the specific population of standard-risk patients who did not undergo up-front autologous stem cell transplant. By comparing a fixed two-year maintenance period against indefinite therapy, the study isolated the variable that mattered most to patients and oncologists alike. The result, showing no survival difference between the two arms, shifts the conversation from “how long should we treat?” to “who can safely stop?”
The practical stakes are significant. Patients who stop at two years avoid years of additional drug exposure. A reasonable hypothesis, supported by the logic of the trial design, is that these patients would accumulate fewer second primary malignancies and preserve physical functioning better over five years compared with those continuing indefinitely. The ENDURANCE data do not yet provide granular adverse-event breakdowns or quality-of-life scores to confirm that expectation, but the survival equivalence alone removes the strongest argument for indefinite therapy in this population.
ENDURANCE trial results and the supporting evidence base
The ENDURANCE study, listed on ClinicalTrials.gov as NCT01863550, enrolled standard-risk newly diagnosed myeloma patients and randomized them to either 24 months of lenalidomide maintenance or continuation until disease progression. The trial excluded patients planning up-front transplant, focusing on a group that represents a large share of myeloma diagnoses in older adults who receive proteasome inhibitor–based induction without immediate high-dose chemotherapy.
The primary finding, reported in the New England Journal of Medicine in an analysis of continuous versus fixed-duration maintenance, showed that overall survival curves for the two arms were not meaningfully different. Progression-free survival favored longer treatment to a modest degree, but this did not translate into a survival advantage over the follow-up period reported. In other words, patients on the two-year plan tended to experience earlier biochemical or radiographic relapse, yet they lived just as long once subsequent therapies were taken into account.
This result arrived against a backdrop of earlier work that had already begun testing fixed-duration strategies. The phase 3 GMMG-MM5 trial, conducted in transplant-eligible patients, compared a fixed two-year course of lenalidomide maintenance against a strategy that stopped treatment when patients reached deep responses, as described in a publication in Blood. That study established that time-limited approaches could be tested safely, though it addressed a different, generally younger patient population and used response depth rather than a calendar-based cutoff as the stopping rule.
Other research has explored whether deep molecular remission can guide when to stop. Trials using measurable residual disease (MRD) testing, such as MRD-guided discontinuation cohorts and observational efforts like MRD2STOP, have suggested that patients who achieve sustained MRD negativity may be able to discontinue maintenance without compromising medium-term outcomes. Additional prospective work is underway in MRD-negative remission, including studies that explicitly build stopping decisions around highly sensitive MRD assays. Together, these lines of evidence point toward a future in which both time on therapy and depth of response inform individualized maintenance plans.
Gaps in the data and what patients should watch for next
The ENDURANCE results are clear on the survival question but leave several important areas unresolved. The trial has not yet reported detailed rates of second primary malignancies by arm, which would help quantify the long-term safety advantage of stopping earlier. Lenalidomide carries a known risk of secondary cancers with prolonged use, and the two-year cutoff was partly motivated by that concern. Without published hazard ratios for this specific endpoint, the magnitude of any safety benefit from stopping remains an inference rather than a measured outcome.
Quality-of-life data present a similar gap. Patients and clinicians want to know whether stopping maintenance translates into measurable improvements in physical functioning, energy, and daily activity. The trial protocol collected patient-reported outcomes, but the published results have not yet broken these down in a way that allows direct comparison between arms at later time points. This information would strengthen the case for a two-year limit by showing that survival parity is accompanied by better day-to-day well-being.
Another unresolved question is how broadly the ENDURANCE findings should be applied beyond the exact population studied. The trial focused on standard-risk cytogenetics and patients who did not receive early transplant. It does not address high-risk features, nor does it directly inform decisions after autologous transplant, where the disease biology and treatment sequencing differ. Clinicians will need to be cautious about extrapolating to those groups until dedicated trials or subgroup analyses are available.
Patients should also be aware that progression-free survival was somewhat longer in the continuous-therapy arm. For some individuals, particularly those who value delaying biochemical relapse even if it does not extend overall survival, that difference may still matter. The trade-off is more months or years on daily medication, with attendant side effects and monitoring, in exchange for a longer interval before the next line of therapy is needed. Others may prioritize time off treatment and accept an earlier relapse, knowing that subsequent options remain available.
How this may change conversations in the clinic
For many oncologists, the ENDURANCE data will prompt a recalibration of default recommendations. Rather than presenting indefinite lenalidomide as the unquestioned standard, clinicians can now discuss a two-year stopping point as an evidence-based option for standard-risk patients treated without early transplant. This shifts the decision from a one-way street into a shared discussion about values, side effects, and the patient’s tolerance for uncertainty.
In practice, that conversation may include a review of current symptoms and lab trends as the two-year mark approaches, along with a discussion of what relapse monitoring will look like after stopping. Some centers may incorporate MRD testing, where available, as an additional layer of reassurance, even though ENDURANCE itself did not require MRD negativity to stop. Patients might hear more explicit framing such as: “We have strong evidence that stopping now does not shorten life expectancy in people like you; here are the pros and cons of continuing anyway.”
Health systems and payers are also likely to take notice. Lenalidomide is expensive, and years of additional treatment across thousands of patients translate into substantial costs. When a large, cooperative-group phase 3 trial shows no survival benefit to indefinite therapy in a common clinical scenario, pressure builds to align practice with the more efficient strategy. That alignment, however, will depend on dissemination of the data, updates to guidelines, and comfort among front-line clinicians in changing long-standing habits.
For patients and families navigating decisions today, the key takeaway is that standard-risk myeloma treated without early transplant no longer comes with an automatic expectation of lifelong lenalidomide maintenance. A two-year course followed by close observation is now a data-supported path rather than a gamble. As additional analyses from ENDURANCE and related MRD-guided studies emerge, the field will likely refine who can safely stop, when, and under what monitoring conditions. Until then, the new evidence gives patients more room to ask whether continuing maintenance is helping them live longer-or simply keeping them on treatment longer than they need to be.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
